Compass Pathways reported Q1 2026 results showing a $466 million cash position, bolstered by recent financing and warrant exercises. The FDA granted rolling submission and review status for COMP360's new drug application in treatment-resistant depression, based on Phase 3 trial data, with the final NDA submission targeted for Q4 2026. The company also posted a GAAP loss of $0.98 per share, beating analyst expectations by $0.05, and separately announced positive Phase 2 results for abdakibart in a severe skin condition called hidradenitis suppurativa.
Rolling review status from the FDA is a meaningful regulatory accelerant — it means the agency begins evaluating sections of the application as they're submitted rather than waiting for the full package, compressing the timeline to a potential approval decision. With $466 million in cash, Compass has a credible runway to reach commercialization without near-term dilution risk. A second pipeline asset, abdakibart, now advancing toward Phase 3 adds optionality that the market may not be fully pricing in.
Early Q3 2026: 26-week Part B data from the COMP006 trial for COMP360 expected to be released. Q4 2026: Final new drug application submission to the FDA. No specific date confirmed yet for Phase 3 start of abdakibart.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief